U.S. Induced Pluripotent Stem Cell (iPSC) Market Share, Size, Trends, Industry Analysis Report, By Derived Cell (Hepatocytes, Fibroblasts, Neural Cells, Amniotic Cells, Cardiomyocytes, Others); By Workflow; By Application; Segment Forecast, 2024 - 2032

U.S. Induced Pluripotent Stem Cell (iPSC) Market Share, Size, Trends, Industry Analysis Report, By Derived Cell (Hepatocytes, Fibroblasts, Neural Cells, Amniotic Cells, Cardiomyocytes, Others); By Workflow; By Application; Segment Forecast, 2024 - 2032

The global Induced Pluripotent Stem Cell (iPSC) market size is expected to reach USD 4,355.56 Million by 2032, according to a new study by Polaris Market Research. The report “iPSC Market Share, Size, Trends, Industry Analysis Report, By Derived Cell (Hepatocytes, Fibroblasts, Neural Cells, Amniotic Cells, Cardiomyocytes, Others); By Workflow; By Application; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growing elderly population, rising cases of chronic diseases, and advancements in research and development are contributing to the increasing growth of the iPSC market. This growth is attracting significant investments from pharmaceutical companies worldwide, who are interested in advanced drug development and testing, and is thereby catering to the overall growth of the iPSC market.

The overall stem cell workflow, although complex, presents a unique opportunity for new entrants in the production of iPSC. Some of the critical and complex processes involved in the production of iPSC include generation, reprogramming, and differentiation into various desired cell types, which require both expertise and resources. However, with the option of commercial iPSC-derived cell purchase or outsourcing programming, new entrants are encouraged to explore this field and contribute to its growth.

With several market entry options available, several trends are observed, such as concentrated efforts on reprogramming and in-house differentiation, purchase of iPSC-derived cell types from off-the-shelf product portfolios, or entering into agreements with third-party purveyors to produce customized models. This trend has spurred a range of possibilities that will feature iPSC-based models for a host of disease models, phenotypic assays, and toxicology testing.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below:

Biopharmaceuticals are drugs that are derived from microbiological sources such as hormones, vaccines, monoclonal antibodies, therapeutic enzymes, blood factors, and so on. These drugs are highly specific and have opened up new avenues in healthcare, such as personalized medicine. This approach involves treating various diseases or conditions using specific biomolecules depending on the patient's physiological, biological, and genetic makeup. As conventional pharmaceuticals have limited applicability and there are few players in the biotechnology industry, the growth of cell culture technology has been fueled.

iPSC Market Report Highlights

- In 2023, the global market witnessed significant growth, with cardiomyocytes emerging as the dominant segment. This is because cardiomyocytes, specialized muscle cells in the heart responsible for its contraction and pumping action, have gained significant attention due to their potential for therapeutic applications.

- The regenerative medicine industry is projected to experience a substantial growth rate in the upcoming years. Regenerative medicine involves therapeutic techniques that target the repair, replacement, or regeneration of tissues or organs in order to restore normal function in individuals who are suffering from injury or disease.

- The North American region dominated the global market, owing to its extensive research and innovation in the field of biomedical science.

- The global key market players include Astellas Pharma Inc., Axol Bioscience Ltd., Cynata Therapeutics Limited, Fate Therapeutics, FUJIFILM Holdings Corporation (Cellular Dynamics), Ncardia, REPROCELL Inc., Takara Bio Inc., Thermo Fisher Scientific Inc., ViaCyte, Inc, etc.

Polaris Market Research has segmented the iPSC market report based on derived cell, workflow, application, and region:

iPSC, Derived Cell Outlook (Revenue - USD Million, 2019 - 2032)

- Hepatocytes

- Fibroblasts

- Neural Cells

Excitatory Neurons

Inhibitory Neurons

- Amniotic Cells

- Cardiomyocytes

- Others

iPSC, Workflow Outlook (Revenue - USD Million, 2019 - 2032)

- Reprogramming

- Cell Culture

- Cell Characterization / Analysis

- Engineering

- Others

iPSC, Application Outlook (Revenue - USD Million, 2019 - 2032)

- Manufacturing

- Academic Research

- Drug Development & Discovery

- Toxicity Screening

- Regenerative Medicine

iPSC, Regional Outlook (Revenue - USD Million, 2019 - 2032)

- North America

U.S.

Canada

- Europe

Germany

UK

France

Italy

Spain

Austria

Netherlands

Rest of Europe

- Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Australia

Rest of APAC

- Latin America

Argentina

Brazil

Mexico

Rest of Latin America

- Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of MEA